Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis.
Anthony James OconGeorge ReedDimitrios A PappasJeffrey R CurtisJoel M KremerPublished in: Annals of the rheumatic diseases (2021)
Over preceding 6-month and 1-year intervals, initiating glucocorticoids in steroid-naïve RA patients is associated with increased risk of CVE at daily doses ≥5 mg and increased cumulative dose and duration of use. No association with risk for CVE was found with daily prednisone of ≤4 mg or shorter cumulative doses and durations.
Keyphrases
- cardiovascular events
- end stage renal disease
- coronary artery disease
- cardiovascular disease
- physical activity
- ejection fraction
- newly diagnosed
- chronic kidney disease
- rheumatoid arthritis
- prognostic factors
- patient reported outcomes
- type diabetes
- systemic lupus erythematosus
- disease activity
- ankylosing spondylitis
- interstitial lung disease